Modality
ADC
MOA
JAK1/2i
Target
CDK4/6
Pathway
Incretin
MesoPNHFSGS
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
Jun 2017
→ Jun 2029
Phase 3Current
NCT04070305
159 pts·Meso
2017-06→TBD·Not yet recruiting
NCT04478592
456 pts·FSGS
2022-05→2028-05·Terminated
NCT07688477
2,520 pts·Meso
2025-10→2029-06·Not yet recruiting
3,135 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-05-052.1y awayPh3 Readout· FSGS
2029-06-053.2y awayPh3 Readout· Meso
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P3
Not yet…
P3
Termina…
P3
Not yet…
Catalysts
Ph3 Readout
2028-05-05 · 2.1y away
FSGS
Ph3 Readout
2029-06-05 · 3.2y away
Meso
TerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04070305 | Phase 3 | Meso | Not yet recr... | 159 | EFS |
| NCT04478592 | Phase 3 | FSGS | Terminated | 456 | EASI-75 |
| NCT07688477 | Phase 3 | Meso | Not yet recr... | 2520 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| Talazumab | Zealand Pharma | Phase 1/2 | WEE1 |